Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Results from phase IV study of Mydcombi (phenylephrine + tropicamide) to characterize the lowest deliverable dose for mydriasis – Eyenovia

Written by | 10 May 2024

Eyenovia announced results from a Phase IV study of Mydcombi designed to characterize the lowest deliverable dose for mydriasis (pupil dilation). Mydcombi is the only FDA-approved fixed dose… read more.

Novabay Pharmaceuticals and Eyenovia collaborate to co-promote ophthalmic products in the USA

Written by | 20 Mar 2024

NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay… read more.

FDA approves APP 13007 (clobetasol propionate ophthalmic suspension 0.05%) for post operative inflammation and pain following ocular surgery – Eyenovia

Written by | 10 Mar 2024

The FDA has approved clobetasol propionate ophthalmic suspension 0.05% (APP 13007) by Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics. This suspension for the treatment of post-operative inflammation and pain… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.